RT Journal Article
SR Electronic
T1 Longitudinal multi-omics analysis identifies responses of megakaryocytes, erythroid cells and plasmablasts as hallmarks of severe COVID-19 trajectories
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.11.20187369
DO 10.1101/2020.09.11.20187369
A1 Bernardes, Joana P.
A1 Mishra, Neha
A1 Tran, Florian
A1 Bahmer, Thomas
A1 Best, Lena
A1 Blase, Johanna I.
A1 Bordoni, Dora
A1 Franzenburg, Jeanette
A1 Geisen, Ulf
A1 Josephs-Spaulding, Jonathan
A1 Köhler, Philipp
A1 Künstner, Axel
A1 Rosati, Elisa
A1 Aschenbrenner, Anna C.
A1 Bacher, Petra
A1 Baran, Nathan
A1 Boysen, Teide
A1 Brandt, Burkhard
A1 Bruse, Niklas
A1 Dörr, Jonathan
A1 Dräger, Andreas
A1 Elke, Gunnar
A1 Ellinghaus, David
A1 Fischer, Julia
A1 Forster, Michael
A1 Franke, Andre
A1 Franzenburg, Sören
A1 Frey, Norbert
A1 Friedrichs, Anette
A1 Fuß, Janina
A1 Glück, Andreas
A1 Hamm, Jacob
A1 Hinrichsen, Finn
A1 Hoeppner, Marc P.
A1 Imm, Simon
A1 Junker, Ralf
A1 Kaiser, Sina
A1 Kan, Ying H.
A1 Knoll, Rainer
A1 Lange, Christoph
A1 Laue, Georg
A1 Lier, Clemens
A1 Lindner, Matthias
A1 Marinos, Georgios
A1 Markewitz, Robert
A1 Nattermann, Jacob
A1 Noth, Rainer
A1 Pickkers, Peter
A1 Rabe, Klaus F.
A1 Renz, Alina
A1 Röcken, Christoph
A1 Rupp, Jan
A1 Schaffarzyk, Annika
A1 Scheffold, Alexander
A1 Schulte-Schrepping, Jonas
A1 Schunck, Domagoj
A1 Skowasch, Dirk
A1 Ulas, Thomas
A1 Wandinger, Klaus-Peter
A1 Wittig, Michael
A1 Zimmermann, Johannes
A1 Busch, Hauke
A1 Hoyer, Bimba
A1 Kaleta, Christoph
A1 Heyckendorf, Jan
A1 Kox, Matthijs
A1 Rybniker, Jan
A1 Schreiber, Stefan
A1 Schultze, Joachim
A1 Rosenstiel, Philip
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/09/18/2020.09.11.20187369.abstract
AB The pandemic spread of the potentially life-threatening disease COVID-19 requires a thorough understanding of the longitudinal dynamics of host responses. Temporal resolution of cellular features associated with a severe disease trajectory will be a pre-requisite for finding disease outcome predictors. Here, we performed a longitudinal multi-omics study using a two-centre German cohort of 13 patients (from Cologne and Kiel, cohort 1). We analysed the bulk transcriptome, bulk DNA methylome, and single-cell transcriptome (>358,000 cells, including BCR profiles) of peripheral blood samples harvested from up to 5 time points. The results from single-cell and bulk transcriptome analyses were validated in two independent cohorts of COVID-19 patients from Bonn (18 patients, cohort 2) and Nijmegen (40 patients, cohort 3), respectively. We observed an increase of proliferating, activated plasmablasts in severe COVID-19, and show a distinct expression pattern related to a hyperactive cellular metabolism of these cells. We further identified a notable expansion of type I IFN-activated circulating megakaryocytes and their progenitors, indicative of emergency megakaryopoiesis, which was confirmed in cohort 2. These changes were accompanied by increased erythropoiesis in the critical phase of the disease with features of hypoxic signalling. Finally, projecting megakaryocyte- and erythroid cell-derived co-expression modules to longitudinal blood transcriptome samples from cohort 3 confirmed an association of early temporal changes of these features with fatal COVID-19 disease outcome. In sum, our longitudinal multi-omics study demonstrates distinct cellular and gene expression dynamics upon SARS-CoV-2 infection, which point to metabolic shifts of circulating immune cells, and reveals changes in megakaryocytes and increased erythropoiesis as important outcome indicators in severe COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The patients consented to the sampling of biomaterials, analytic processing of the biomaterials and genetic analysis, the study was approved by the independent ethical review board of Kiel University (ref number: D 466/20) and Cologne (identifier: 20-1295). 8 healthy donors were included as controls at a single timepoint in the framework of the DZHK study (ethics vote ref number: D 441/16). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAs of now, data will be available upon request.